Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 526 to 550 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
526 decreased catalytic activity (GO:0003824) type I iodothyronine deiodinase (PR:000006480) 1009: Inhibition, Deiodinase 1
527 increased inhibitory postsynaptic potential (GO:0060080) 1012: Increased, Inhibitory postsynaptic potential
528 decreased negative regulation of synaptic transmission (GO:0050805) GABA receptor complex (GO:1902710) 1015: Increased, Neuronal synaptic inhibition
529 increased gene expression (GO:0010467) UDP-glucuronosyltransferase (PR:000024849) 1020: Increased, induction of UDPGT's in liver
530 increased hormone catabolic process (GO:0042447) thyroxine (CHEBI:30660) 1021: Increased, T4/T3 catabolism
531 increased fat cell differentiation (GO:0045444) 1029: Increased, adipogenesis
532 increased secretion (GO:0046903) eukaryotic protein (PR:000036194) 1032: Increased, secretion of local growth factors
533 increased mesenchymal cell proliferation (GO:0010463) mesenchymal cell (CL:0008019) 1033: Increased, proliferation of mesenchymal cells
534 increased gene expression (GO:0010467) IGF-like family receptor 1 (mouse) (PR:Q3U4N7) 1034: Increased, IGF-1 (mouse)
535 increased Fibrosarcoma (MESH:D005354) 1035: Increased, Firbrosarcoma
536 increased liposarcoma (MESH:D008080) 1036: Increased, liposarcoma
537 increased hemangiosarcoma (MESH:D006394) 1037: Increased, hemagiosarcoma
538 increased beta-2 adrenergic receptor binding (GO:0031698) beta-2 adrenergic receptor (PR:000001193) 1038: Activation, beta-2 adrenergic receptor
539 increased beta2-adrenergic receptor activity (GO:0004941) beta-2 adrenergic receptor (PR:000001193) 1039: Increased activity, beta-2 adrenergic receptor
540 increased relaxation of smooth muscle (GO:0044557) 1040: relaxation, smooth muscle
541 increased cell proliferation (GO:0008283) smooth muscle cell (CL:0000192) 1042: Proliferation/Clonal Expansion, smooth muscle
542 increased hypertrophy (MESH:D006984) smooth muscle tissue (UBERON:0001135) 1043: Hypertrophy/hyperplasia, smooth muscle
543 increased leiomyoma (MESH:D007889) 1044: Promotion, mesovarian leiomyomas
544 decreased estradiol (CHEBI:23965) 1045: Decreased, Ovarian E2
545 decreased follicle-stimulating hormone secretion (GO:0046884) Follicle stimulating hormone (CHEBI:81569) 1049: Increased, secrection of FSH from anterior pituitary
546 increased hyperplasia (MESH:D006965) stromal cell of ovary (CL:0002132) 1051: Hyperplasia, ovarian stromal cells
547 increased hyperplasia (MESH:D006965) epithelium of female gonad (UBERON:0004911) 1052: Hyperplasia, ovarian epithelium
548 increased Granular Cell Tumor (MESH:D016586) 1054: Promotion, ovarian granular cell tumors
549 decreased bile (UBERON:0001970) 1058: Decreased, bile flow
550 abnormal lipid metabolic process (GO:0006629) 1060: Alteration, lipid metabolism